Review: Selegiline leads to a small short-term improvement in cognition and activities of daily living in Alzheimer disease

Luxenberg, Jay S.
July 2002
ACP Journal Club;Jul/Aug2002, Vol. 137 Issue 1, p10
Academic Journal
Provides information on a study that investigated whether selegiline improve cognitive performance, functional ability, emotional state and global response in patients with Alzheimer disease. Data sources; Study selection; Main results; Conclusions.


Related Articles

  • Primary care. Singer, Karl // Patient Care;1/15/1998, Vol. 32 Issue 1, p111 

    Presents a study entitled `A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease. The Alzheimer's Disease Cooperative Study,' by M. Sano, C. Ernesto, R.G. Thomas, et al in the 1997 issue of the N Engl J Med.

  • Selegiline and vitamin E for Alzheimer's disease. Andolsek, Kathryn M. // American Family Physician;1/1/1998, Vol. 57 Issue 1, p147 

    Presents information on Alzheimer's disease while focusing on an investigation by Sano and associates pertaining to the use of selegiline (a monoamine oxidase inhibitor), alpha-tocopherol (vitamin E) in patients with severe Alzheimer's disease. Participants in the study; Objective of the study;...

  • Antioxidants and Alzheimer's.  // Patient Care;6/15/1997, Vol. 31 Issue 11, p12 

    Discusses the significant benefits of the use of the antioxidants selegiline and alpha-tocopherol (vitamin E) for patients with moderately severe Alzheimer's disease. Assessment of the patients under study at three-month interval for two years; Impact of the current treatment of the disease on...

  • 3H-Deprenyl and 3H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β-amyloid in Alzheimer brain. Marutle, Amelia; Gillberg, Per-Göran; Bergfors, Assar; Wenfeng Yu; Ruiqing Ni; Nennesmo, Inger; Voytenko, Larysa; Nordberg, Agneta // Journal of Neuroinflammation;2013, Vol. 10 Issue 1, p1 

    Background: The pathological features in Alzheimer's disease (AD) brain include the accumulation and deposition of β-amyloid (Aβ), activation of astrocytes and microglia and disruption of cholinergic neurotransmission. Since the topographical characteristics of these different pathological...

  • Alzheimer's war. Marcus, Mary Brophy // U.S. News & World Report;05/05/97, Vol. 122 Issue 17, p77 

    Mentions a study which found that both vitamin E and a prescription drug used against Parkinson's disease seem to slow the progress of Alzheimer's disease. The drug, selegiline; The study as reported by Mary Sano in a 1997 issue of `New England Journal of Medicine.'

  • Study reveals new treatments that may delay Alzheimer's.  // Hudson Valley Business Journal;04/28/97, Vol. 7 Issue 26, p24 

    Reports on the results of a research on the effectiveness of vitamin E or selegiline in slowing the progression of Alzheimer's disease. Potentials of vitamin E or selegiline in treating the disease; Previous research on the therapeutic applications of vitamin E. INSET: Alzheimer's treatments...

  • SELEGILINE AND VITAMIN E IN ALZHEIMER'S DISEASE. Adelman, Alan // Journal of Family Practice;Aug1997, Vol. 45 Issue 2, p98 

    The article presents a study which examined whether selegiline and vitamin E slow the progression of Alzheimer's disease (AD). The population was made up of 341 elderly patients recruited. All the participants had AD of moderate severity as measured by a Clinical Dementia Rating of 2. There was...

  • Clinical Applications of MAO-Inhibitors. Riederer, P.; Lachenmayer, L.; Laux, G. // Current Medicinal Chemistry;Aug2004, Vol. 11 Issue 15, p2033 

    Monoamine oxidase inhibitors (MAO-I) have been useful in the treatment of both psychiatric and neurological disorders over centuries. Here we focus on the development of this drug treatment. Focus is given on the use of irreversible MAO-I's as well as on reversible ones. Benefit and side effects...

  • Chronic Exposure of Rats to Cognition Enhancing Drugs Produces a Neuroplastic Response Identical to that Obtained by Complex Environment Rearing. Murphy, Keith J.; Foley, Andrew G.; O'Connell, Alan W.; Regan, Ciaran M. // Neuropsychopharmacology;Jan2006, Vol. 31 Issue 1, p90 

    Recent data suggest that Alzheimer's patients who discontinue treatment with cholinesterase inhibitors have a significantly delayed cognitive decline as compared to patients receiving placebo. Such observations suggest cholinesterase inhibitors to provide a disease-modifying effect as well as...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics